RS20080257A - Indolone compounds useful to treat cognitive impairment - Google Patents

Indolone compounds useful to treat cognitive impairment

Info

Publication number
RS20080257A
RS20080257A RSP-2008/0257A RSP20080257A RS20080257A RS 20080257 A RS20080257 A RS 20080257A RS P20080257 A RSP20080257 A RS P20080257A RS 20080257 A RS20080257 A RS 20080257A
Authority
RS
Serbia
Prior art keywords
cognitive impairment
compounds useful
treat cognitive
indolone compounds
indolone
Prior art date
Application number
RSP-2008/0257A
Other languages
English (en)
Inventor
Thomas P. Blackburn
Original Assignee
Helicon Therapeutics Inc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helicon Therapeutics Inc., filed Critical Helicon Therapeutics Inc.,
Publication of RS20080257A publication Critical patent/RS20080257A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Predmetni pronalazak obezbeđuje postupak lečenja pacijenta koji pati od kognitivnog oštećenja ili kognitivnog poremećaja, koji podrazumeva primenu jedinjenja indolona u količini koja je delotvorna za lečenje kognitivnog oštećenja ili kognitivnog poremećaja tog pacijenta.
RSP-2008/0257A 2005-12-09 2006-12-08 Indolone compounds useful to treat cognitive impairment RS20080257A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74885105P 2005-12-09 2005-12-09
PCT/US2006/046826 WO2007070362A1 (en) 2005-12-09 2006-12-08 Indolone compounds useful to treat cognitive impairment

Publications (1)

Publication Number Publication Date
RS20080257A true RS20080257A (en) 2009-05-06

Family

ID=37903540

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2008/0257A RS20080257A (en) 2005-12-09 2006-12-08 Indolone compounds useful to treat cognitive impairment

Country Status (24)

Country Link
EP (2) EP1957067B1 (sr)
JP (1) JP5336194B2 (sr)
KR (1) KR20080077646A (sr)
CN (1) CN101378750B (sr)
AT (1) ATE480234T1 (sr)
AU (1) AU2006326665B2 (sr)
BG (1) BG110157A (sr)
BR (1) BRPI0620034A2 (sr)
CA (1) CA2633829A1 (sr)
CZ (1) CZ2008423A3 (sr)
DE (1) DE602006016849D1 (sr)
EA (1) EA200870027A1 (sr)
ES (1) ES2349675T3 (sr)
HK (1) HK1127736A1 (sr)
HR (1) HRP20080254A2 (sr)
IL (1) IL192022A0 (sr)
IS (1) IS8733A (sr)
MX (1) MX2008007377A (sr)
NO (1) NO20083042L (sr)
PL (1) PL386471A1 (sr)
RS (1) RS20080257A (sr)
SK (1) SK500262008A3 (sr)
WO (1) WO2007070362A1 (sr)
ZA (1) ZA200805285B (sr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2527324A4 (en) 2010-01-20 2013-08-07 Mitsubishi Gas Chemical Co CYANATE STARTER COMPOUND AND HARDENING PRODUCT THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK69693D0 (da) * 1993-06-14 1993-06-14 Neurosearch As Farven lilla
WO2002060392A2 (en) 2001-01-31 2002-08-08 Synaptic Pharmaceutical Corporation Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
AU2003259074A1 (en) * 2002-08-07 2004-02-25 Synaptic Pharmaceutical Corporation Gal3 antagonists for the treatment of neuropathic pain
AU2003259759A1 (en) * 2002-08-07 2004-02-25 Synaptic Pharmaceutical Corporation Gal3 receptor antagonists for the treatment of affective disorders
WO2004014854A1 (en) * 2002-08-07 2004-02-19 Synaptic Pharmaceutical Corporation 3-imino-2-indolones for the treatment of depression and/or anxiety

Also Published As

Publication number Publication date
MX2008007377A (es) 2008-10-29
EP1957067B1 (en) 2010-09-08
CN101378750B (zh) 2012-07-18
ES2349675T3 (es) 2011-01-10
DE602006016849D1 (de) 2010-10-21
IS8733A (is) 2008-06-20
HK1127736A1 (en) 2009-10-02
IL192022A0 (en) 2009-08-03
CA2633829A1 (en) 2007-06-21
ATE480234T1 (de) 2010-09-15
EA200870027A1 (ru) 2009-12-30
SK500262008A3 (sk) 2009-03-05
CZ2008423A3 (cs) 2009-08-05
EP2241316A1 (en) 2010-10-20
AU2006326665A1 (en) 2007-06-21
JP2009518431A (ja) 2009-05-07
WO2007070362A1 (en) 2007-06-21
CN101378750A (zh) 2009-03-04
KR20080077646A (ko) 2008-08-25
AU2006326665B2 (en) 2012-11-15
ZA200805285B (en) 2009-12-30
BRPI0620034A2 (pt) 2011-10-25
HRP20080254A2 (en) 2008-09-30
EP1957067A1 (en) 2008-08-20
BG110157A (en) 2008-12-30
PL386471A1 (pl) 2009-04-14
JP5336194B2 (ja) 2013-11-06
NO20083042L (no) 2008-09-08

Similar Documents

Publication Publication Date Title
MX2007016469A (es) Metodos de tratamiento utilizando ansamicinas de hidroquinona.
MX2009013082A (es) Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.
MX2007011859A (es) Compuestos mejorados farmacocineticamente.
TW200626068A (en) Active compounds for seed treatment
TW200637866A (en) Amino-imidazolones for the inhibition of β-secretase
EA200600048A1 (ru) Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
TW200730523A (en) Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
IL175770A0 (en) Novel use of peptide compounds for treating central neuropathic pain
TW200510301A (en) Novel compounds
TW200510303A (en) Novel compounds
MX2009005649A (es) Tratamiento para mieloma multiple.
MA29785B1 (fr) Agents permettant de prevenir et de traiter des troubles entrainant la modulation des recepteurs ryr
WO2006024018A3 (en) Compositions for treating nociceptive pain
TW200733976A (en) Method for the treatment of cognitive dysfunction
MX2010002674A (es) Moduladores de gamma secretasa.
EA200900021A1 (ru) Пептидные соединения для лечения рефрактерного эпилептического статуса
MY177001A (en) Phenothiazine compounds for treating mild cognitive impairment
TW200605871A (en) Carboxamido opioid compounds
WO2007047447A3 (en) Diuretic-like compound analogs useful for regulation of central nervous system disorders
TW200724140A (en) Hydantoin compounds
TW200642690A (en) Composition for treating central nervous system disorders
MX2009005351A (es) Compuestos utiles para tratar trastornos neurodegenerativos.
TN2010000155A1 (en) Organic compounds
TW200744577A (en) Method for treating osteoarthritis
TW200742580A (en) Methods for treating nephrolithiasis